Aequus Pharmaceuticals Inc (AQSZF)

Overview

Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company established in 2013 with its headquarters situated in Vancouver, Canada. The company is dedicated to the commercialization of value-added products specifically targeting specialty therapeutic areas within the Canadian market. Aequus Pharmaceuticals Inc. prides itself on its strategic collaborations and its focus on developing and marketing products that address unmet medical needs, with its efforts concentrated on enhancing patient care in various therapeutic fields.

Products and Services

• ZIMED PF

  A preservative-free bimatoprost prescription drug, ZIMED PF is designed for the treatment of glaucoma, a condition characterized by increased pressure in the eye that can lead to loss of vision. By providing a preservative-free option, Aequus Pharmaceuticals Inc. addresses the needs of patients who may be sensitive to preservatives commonly found in ophthalmic solutions, offering a safer alternative for those requiring long-term medication for glaucoma management.

• REV-0100

  Currently in the pre-clinical trial phase, REV-0100 is a therapeutic candidate under development for the treatment of Stargardt disease, a genetic eye disorder that causes vision loss. This reflects the company's commitment to advancing treatments for rare and underserved conditions. Aequus Pharmaceuticals Inc. has entered into a strategic collaboration with reVision, combining expertise and resources in a joint effort to develop an effective therapy for this debilitating disease.